BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
Morgan Stanley maintains overweight on Biocon
Steady business fundamentals. See improvement in the second wave of Biosimilar assets. Expect price earnings ratios to expand in the near term.